VolitionRx Partners with Two Market Access Consulting Agencies to Support Market Access of NuQ(R) Colorectal Cancer Tests in Europe
In this press relese, we said: “Market access and optimal reimbursement are critical considerations that require careful planning and strategic execution in the European Union given the diversity of the region’s governments, payers and regulating healthcare organizations. As VolitionRx’s counsel for access into several European countries, we will develop a reimbursement roadmap outlining specific aspects in each of the target countries and potential actions to optimize market access and provide value for investors.”
VolitionRx press release